PAVM - CONSENSUS CO - PAVmed Inc.

This market valuation of PAVmed Inc. (PAVM) reflects a consensus forecast where the key metric stands at 36.47. The business operates as a hub for advanced development, creating EsoGuard for esophageal tumor detection and CarpX tools. High profitability is achieved by licensing technology rights to third parties. A balanced portfolio, ranging from digital monitoring to diagnostics, minimizes risks, although it requires significant implementation costs.

This indicator represents the weighted average of target prices from industry experts, reflecting the fundamental value of the business through the lens of expected returns. By analyzing the market consensus target for the stock, an investor can assess the growth potential of PAVmed Inc. (PAVM) in an environment where the company's operating cash flow still depends on inertial sales of diagnostic systems and has not yet reached the stage of stable profitability.